We’re proud to announce the launch of a dedicated website for our investment arm, InSynchrony Ventures. InSynchrony provides financing to early staged companies and InSymbiosis provides a unique drug development platform and expertise to enable those early staged programs to advance towards key milestones. This combined effort brings capital, knowledge and expertise together at the right time to provide promising drug assets with the key ingredients for success.

InSynchrony’s portfolio of early stage drug development companies has exciting announcements! Atriva Therapeutics closed €3 MN in seed financing, and Cetya Therapeutics received a $ 240,000 STTR grant.

For more news on InSynchrony, check out the dedicated blog.